Company Overview and News

iSignthis set to gain from new Australian anti-money laundering law

iSignthis (ASX:ISX) is expected to gain from the proposed bill to strengthen Australia’s anti-money laundering (AML) laws, including bringing bitcoin providers under the remit of the government's financial intelligence unit.
Upvote Downvote

iSignthis’ subsidiary granted eMoney license in Europe

iSignthis’ (ASX:ISX) subsidiary ISXPay, has crossed a major milestone in Europe by securing an eMoney Institution (EMI) license from the Central Bank of Cyprus.
Upvote Downvote

iSignthis grants technology licence to

iSignthis is a payments and identity processing platform that automates know you customer (KYC), anti-money laundering and transaction monitoring services. The company’s Paydentity solution incorporates real time electronic verification to converge remote payment authentication and KYC identification. Industries including foreign exchange trading and gaming/wagering have strict KYC rules to prevent money laundering.
Upvote Downvote

TikForce Ltd to launch tool for comprehensive validation of workers

TikForce Ltd (ASX:TKF) will launch a comprehensive digital work validation pack next week, which will include features such as an automated police check. Over 20% of the Australian workforce, or in excess of two million workers, will need some form of validation for their employment. TikForce’s Digital Work Validation Pack, which will be priced at $49.50, represents a compelling value to businesses and workers.
Upvote Downvote

iSignthis Ltd provides digital identity proofing to options traders

iSignthis Ltd (ASX:ISX) formerly Otis Energy is an intuitive and non-intrusive payment and identification authentication service.
Upvote Downvote

iSignthis Ltd signs on with blockchain platform for increased security

iSignthis Ltd (ASX:ISX) formerly Otis Energy is an intuitive and non-intrusive payment and identification authentication service.
Upvote Downvote

Analyst Briefing

Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...